# References — Recovery & Tissue Repair Peptide Literature — Iron Peptide Innovations

> The aggregated citation list for the Iron Peptide Innovations digest: peer-reviewed sources on BPC-157 and TB-500, with DOIs and PubMed links.

Every source cited across both peptide pages and the comparison, gathered in one place.

## References

The list below aggregates the cited literature across both peptides — BPC-157 and TB-500 — on this digest. Each entry gives authors, title, journal and year, with a DOI and PubMed link where available. A single citation is listed once and referred to by its number throughout the site. Where a source is a review or commentary, the review is what is cited.

## References

[1] Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40131143/
[2] McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40789979/
[3] He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. https://pubmed.ncbi.nlm.nih.gov/36588717/
[4] Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/
[5] Xue XC, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10:1032-1037. https://pubmed.ncbi.nlm.nih.gov/15052688/
[6] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/
[7] Morris DC, et al. A dose-response study of thymosin β4 for the treatment of acute stroke. J Neurol Sci. 2014. https://pubmed.ncbi.nlm.nih.gov/25060418/
[8] Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012. https://pubmed.ncbi.nlm.nih.gov/22074294/
[9] Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin β4 in healthy volunteers. Ann N Y Acad Sci. 2010. https://pubmed.ncbi.nlm.nih.gov/20536472/
[10] Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004. https://pubmed.ncbi.nlm.nih.gov/15329672/
[11] Bock-Marquette I, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004. https://pubmed.ncbi.nlm.nih.gov/15565145/
[12] Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999. https://pubmed.ncbi.nlm.nih.gov/10469335/

---

Peer-reviewed literature, summarized. Not a product, not a prescription, not a clinic.